Adverse allergic reaction to 131I MIBG

Annals of Nuclear Medicine

Volumn 23, Issue 7, 2009, Pages 697-699

  Ishibashi, Naoya ^a   Abe, Katsumi ^a   Furuhashi, Satoru ^a   Fukushima, Shoko ^a   Yoshinobu, Takashi ^a   Takahashi, Motoichiro ^a   Matsumoto, Chiyuki ^a   Fukuda, Kyoko ^a   Kobayashi, Takayuki ^a,b   Mochizuki, Norisuke ^c  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

^c FUJIFILM RI Pharma Co Ltd   (Japan)

Author keywords

131I MIBG; Adverse reactions; Radiopharmaceuticals; Side effect; Skin eruption

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; HYDROCORTISONE; IMMUNOGLOBULIN E; LORATADINE; NORADRENALIN; OLOPATADINE; POTASSIUM IODIDE;

ADULT; ARTICLE; CASE REPORT; ELBOW; ERYTHEMA; ERYTHEMA MULTIFORME; FACE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; MACULOPAPULAR RASH; MALE; NECK; NORADRENALIN BLOOD LEVEL; PATCH TEST; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RADIATION EXPOSURE; RASH; SKIN ALLERGY; SYSTOLIC BLOOD PRESSURE; THORAX WALL; URTICARIA;

3-IODOBENZYLGUANIDINE; ADULT; HUMANS; HYPERSENSITIVITY; MALE; SKIN DISEASES;

EID: 70349336059     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-009-0282-0     Document Type: Article

References (16)

1. SR Hesslewood DH Keeling 1997 Frequency of adverse reactions to radiopharmaceuticals in Europe Eur J Nucl Med 24 1179 1182
2. EB Silberstein J Ryan 1996 Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine J Nucl Med 37 185 192
3. Subcommittee of Safety Issue for the Radiopharmaceuticals, Medical and Pharmaceutical Committee, Japan Radioisotope Association. The twenty-second report on survey of the adverse reaction to radiopharmaceuticals (the 25th survey in 1999). Kaku Igaku. 2001;38:139-50 (in Japanese).
4. Subcommittee of Safety Issue for the Radiopharmaceuticals, Medical and Pharmaceutical Committee, Japan Radioisotope Association. The twenty-first report on survey of the adverse reaction to radiopharmaceuticals (the 24th survey in 1998). Kaku Igaku. 2000;37:237-48 (in Japanese).
5. B Shapiro JE Copp JC Sisson PL Eyre J Wallis WH Beierwaltes 1985 Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases J Nucl Med 26 576 585 (Pubitemid 16033416)
6. J Waton P Tréchot C Loss-Ayav JL Schmutz A Barbaud 2009 Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions Br J Dermatol 160 786 794
7. C Vernassiere P Trechot N Commun JL Schmutz A Barbaud 2004 Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media Contact Dermatitis 50 359 366
8. M Akiyama T Nakada H Sueki R Fujisawa M Iijima 1998 Drug eruption caused by nonionic iodinated X-ray contrast media Acad Radiol 5 Suppl 1 S159 S161
9. N Gao HL Qiao LJ Jia X Tian YW Zhang 2008 Relationships between specific serum IgE, IgG, IFN-gamma level and IFN-gamma, IFNR1 polymorphisms in patients with penicillin allergy Eur J Clin Pharmacol 64 971 977
10. Y Nakagawa Y Sumikawa T Nakamura S Itami I Katayama T Aoki 2006 Urticarial reaction caused by ethanol Allergol Int 55 411 414
11. M Enokibori M Kuge K Mori 1998 Anaphylactoid reaction to maltose 5% solution during spinal anaesthesia Can J Anaesth 45 52 55
12. D Ay C Aktas S Sarikaya A Cetin 2009 An unusual cause of allergy: case report of normal saline solution allergy Am J Emerg Med 27 130.e1 130.e2
13. RS Stern 2005 Utilization of hospital and outpatient care for adverse cutaneous reactions to medications Pharmacoepidemiol Drug Saf 14 677 684
14. AP Jonville JP Dutertre E Autret M Barbellion 1992 Adverse effects of oxybutynin chloride (Ditropan). Evaluation of the official survey of regional pharmacovigilance centers Therapie 47 389 392 (in French)
15. MM Kamada F Twarog DY Leung 1991 Multiple antibiotic sensitivity in a pediatric population Allergy Proc 12 347 350
16. J Nauman J Wolff 1993 Iodide prophylaxis in Poland after the Chernobyl reactor accident: benefits and risks Am J Med 94 524 532